Product Description
MEDI7836 is a human immunoglobulin G1 lambda (IgG1_-YTE) monoclonal antibody, with an Fc modification to reduce metabolic clearance.
Mechanisms of Action: IL13 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02388347 |
D5450C00001 | P1 |
Completed |
Healthy Volunteers |
2016-01-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|